Joint Corp (JYNT)
NASDAQ:JYNT
Want to see JYNT full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.05Last Year’s EPS
-0.05Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights a clear operational and financial inflection driven by near-complete refranchising: revenue growth from continuing operations (+13%), substantial adjusted EBITDA improvement, a return to net income, and disciplined capital allocation (share repurchases and RD buybacks). Management acknowledges near-term headwinds with system-wide sales and comps down (~-4.9% and -4.2% respectively) and some transitional G&A and cash reductions, but provides concrete actions (pricing rollout, marketing, SEO/AI gains, CareCredit, B2B initiatives) and reiterated full-year guidance with a compelling pro-forma margin profile. Overall, the positives from the transformation, profitability gains, and strategic initiatives outweigh the current softness in comps and cash timing risks, supporting an upbeat outlook as refranchising closes and H2 initiatives ramp.Company Guidance
Revenue Growth from Continuing Operations
Revenue from continuing operations increased 13% year-over-year to $14.8 million in Q1 2026, reflecting early benefits from transitioning clinics to continuing operations.
Adjusted EBITDA and Profitability Improvement
Adjusted EBITDA from continuing operations rose to $2.2 million in Q1 2026 versus $46 thousand in Q1 2025; consolidated adjusted EBITDA grew 22% to $3.5 million, demonstrating improved operating leverage.
Net Income Turnaround
Net income from continuing operations was $1.1 million in Q1 2026 compared with a net loss of $506 thousand in Q1 2025, marking a return to profitability on continuing operations.
Refranchising Milestone — Near Completion
Agreements signed to sell 45 company-owned/managed clinics for $2.3 million (April) plus earlier deals and a March LOI will reduce company-owned clinics from 135 at the start of the initiative to just three upon close, effectively creating a pure-play franchisor.
Improved Cash Flow and Free Cash Flow Conversion
Operating cash flow improved by $2.2 million year-over-year, driving a $2.3 million improvement in free cash flow; management expects free cash flow conversion (FCF / adjusted EBITDA) of 60%–70% under the go-forward model.
Capital Allocation — Share and RD Buybacks
Repurchased ~137,000 shares for $1.1 million (avg $8.35) in Q1 with $4.5 million remaining under the $12 million authorization; completed three RD territory buybacks and four in the last 12 months recovering ~ $1.3 million in RD royalties, and expect ~$450k in annual RD royalty reduction from recent buybacks.
Marketing & Digital Momentum
National marketing launched in November showing sequential member growth month-over-month; AI visibility score improved to 78–80 (from ~70), exceeding industry benchmark and driving higher organic traffic and lead quality.
Pricing and Product Initiatives
Pricing optimization rolled out ($5–$10 increases across ~300 clinics) with little/no patient pushback and no meaningful conversion impact; $10 increase targeted enterprise-wide by Q3; launched new 3-month minimum term, AlignOne offering, CareCredit nationwide and first B2B partnership to improve conversion, retention and access.
Reiterate 2026 Guidance and Pro-Forma Targets
Reiterated full-year guidance: system-wide sales $519M–$552M, comp sales -3% to +3%, consolidated adjusted EBITDA $12.5M–$13.5M, and 30–35 new franchise clinic openings; pro-forma mid-2026 model targets adjusted EBITDA margin ~19%–21% and net income margin ~13%–15%.
JYNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JYNT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $8.67 | $8.69 | +0.23% |
Mar 12, 2026 | $8.21 | $8.40 | +2.31% |
Nov 06, 2025 | $7.98 | $7.67 | -3.88% |
Aug 07, 2025 | $10.70 | $10.74 | +0.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Joint Corp (JYNT) report earnings?
Joint Corp (JYNT) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Joint Corp (JYNT) earnings time?
Joint Corp (JYNT) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JYNT EPS forecast?
JYNT EPS forecast for the fiscal quarter 2026 (Q2) is 0.05.